Government-Industry Partnerships Vital To Vaccine Development, Sanofi Senior Executive Writes In Response To Bernie Sanders’ Op-Ed

New York Times: Letter to the Editor: Developing a Zika Vaccine
Elias Zerhouni, president of global research and development for Sanofi

“Re ‘Trump Should Avoid a Bad Zika Deal‘ (Op-Ed, March 11): Bernie Sanders, in our view, doesn’t seem to recognize the importance of government-industry partnerships in protecting the public from potentially devastating infectious diseases. … [T]he United States government is working with a number of different manufacturers who are competing to develop a potential Zika vaccine. As part of this process, the Walter Reed Army Institute of Research has publicly offered its own vaccine candidate for licensing. Under the license agreement — and assuming the vaccine succeeds — my company, Sanofi, would make significant milestone and royalty payments to Walter Reed, allowing the United States government to recoup its investment. … Sanofi has decades of experience in vaccine development and manufacturing. We have partnered with governments and NGOs around the world, ensuring access to lifesaving vaccines at reasonable prices, and we are proud of our continued efforts to do so” (3/21).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.